{"anticipatedPostingDate":"2027-12","denomUnitsSelected":"Participants","description":"PFS was defined as the time from date of randomization to earliest documented PD per RECIST version 1.1 or death due to any cause as assessed by BICR. PD: 20% increase in sum of diameters of target measurable lesions above smallest sum observed, with minimum absolute increase of 5 mm for target disease or unequivocal progression of pre-existing lesions for non-target disease or any new lesion. Censoring details: no adequate baseline assessment, including no disease at baseline: participants were censored to randomization date; no PD, lost to follow-up, withdrawal of consent, PD or death \\>12 (or 16) weeks after the last adequate tumor assessment, and start of new anticancer treatment: participants were censored to last adequate tumor assessment documenting no PD prior to new anticancer therapy, or missed assessments. Analysis was performed using Kaplan Meier method.","reportingStatus":"NOT_POSTED","timeFrame":"From date of randomization to earliest documentation of PD by BICR or death or censoring date, whichever occurred first","title":"Cohort 3: PFS as Assessed by BICR - FAS","type":"SECONDARY"}